Johnson & Johnson
Johnson & Johnson is a U.S.-based healthcare company founded in 1887 that develops, manufactures, and sells products for human health and well-being. It operates through two segments, Innovative Medicine and MedTech, with businesses spanning prescription medicines, surgical and interventional technologies, and other healthcare products sold in virtually all countries.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenuePrescription pharmaceuticals and biologics for major therapeutic areas including immunology, oncology, neuroscience, and cardiovascular disease.
Medical devices and technology used in surgery, orthopaedics, interventional procedures, and vision care.
Customers
Johnson & Johnson sells primarily to healthcare providers, hospitals, clinics, distributors, and other institutional buyers, while prescription medicines ultimately reach patients through physicians and payers. Demand is driven by clinical need, reimbursement, product performance, and physician preference, with wholesalers playing a major role in U.S. distribution. The company also serves public and private healthcare systems across international markets, where local regulation and pricing structures shape purchasing decisions.
Buy surgical, interventional, and orthopaedic devices for procedures and patient care.
Prescribe Innovative Medicine products in immunology, oncology, neuroscience, and cardiovascular care.
Purchase and redistribute products across the U.S. and international healthcare channels.
Influence access, reimbursement, and pricing for both medicines and devices.
End users of therapies and devices, especially in chronic and specialty care settings.
Strategy
Johnson & Johnson is focused on innovation-led growth across its two healthcare segments, supported by heavy R&D investment and a broad global commercial footprint. Management is also using portfolio actions, including the planned separation of Orthopaedics, to sharpen focus and improve capital allocation. New products introduced in the past five years already represent a meaningful share of sales, showing that pipeline execution is central to the strategy.
The company competes on clinical differentiation, intellectual property, and product performance.
Portfolio focus can improve capital allocation and reduce complexity across segments.
International growth depends on reimbursement, regulation, and distribution by country.
Geography
Q1/2026Johnson & Johnson operates in virtually all countries, with the U.S. as its largest market and a broad international footprint across Europe, the Western Hemisphere excluding the U.S., and Asia-Pacific/Africa. The company’s 2025 disclosures show growth across Europe, the Western Hemisphere ex-U.S., and Asia-Pacific/Africa, highlighting meaningful exposure to currency translation and local market conditions. Its global manufacturing, R&D, and distribution network supports both segments and creates exposure to regulatory, political, and supply-chain differences by country.
Share of the revenue the company reports by geography.
Risks
Johnson & Johnson faces intense competition in both pharmaceuticals and devices, where product performance, pricing, reimbursement, and patent protection directly affect sales. The company also has meaningful exposure to cybersecurity, counterfeit products, healthcare reform, and legal proceedings, all of which can disrupt operations or damage reputation. Because it sells globally, currency swings, regulatory changes, and local market instability can also affect reported results and access to markets.
- Competitive pressure across both segmentsImpact: HighLikelihood: High
The company competes on innovation, pricing, reimbursement, and intellectual property in all markets.
Exposure: Innovative Medicine and MedTech
- Patent loss and biosimilar competitionImpact: HighLikelihood: High
Loss of exclusivity can sharply reduce sales of branded medicines.
Exposure - Healthcare reform and pricing pressureImpact: HighLikelihood: High
Government and payer actions can compress pricing and limit access to products.
Exposure: U.S. and international markets
- Cybersecurity and information security incidentsImpact: HighLikelihood: Medium
The company relies on internal and third-party systems for sensitive data, supply chain, and product delivery.
Exposure: Enterprise-wide IT and connected products
- Counterfeit and diverted productsImpact: MediumLikelihood: Medium
Illegal distribution channels can harm patients, reduce sales, and trigger recalls or litigation.
Exposure: Global markets and internet channels
Accounting
Judgemental itemsProduct sales are recognized at transfer of control, but rebates, returns, and discounts reduce net revenue.
Impact: Can materially affect reported sales and margins when estimates change
The company records large accruals for customer rebates and product returns in both segments.
Impact: Affects revenue, receivables, and operating profit
Acquisitions and product portfolios create large intangible balances that must be tested for impairment.
Impact: Potential non-cash charges if product performance weakens
The company faces lawsuits involving product liability, patents, and pricing practices.
Impact: Can create material provisions and cash outflows
Discount rates, asset returns, mortality, and healthcare cost trends affect benefit obligations.
Impact: Can move operating expense and other comprehensive income
Similar listed companies
Publicly listed companies with a comparable business focus.
Merck & Co., Inc.
MRK · Pharmaceutical Preparations
Pfizer, Inc
PFE · Pharmaceutical Preparations
HCA Healthcare, Inc.
HCA · Services-General Medical & Surgical Hospitals, NEC
HCA Healthcare operates a large network of acute-care hospitals, behavioral hospitals, rehabilitation hospitals, ambulatory surgery centers, and endoscopy…
Johnson Controls International plc
JCI · Air-Cond & Warm Air Heatg Equip & Comm & Indl Refrig Equip
Johnson Controls International plc designs, manufactures, installs, and services building systems that control climate, safety, security, and energy use.
AstraZeneca PLC
AZN · Pharmaceutical Preparations
AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines.
Boston Scientific Corporation
BSX · Surgical & Medical Instruments & Apparatus
Boston Scientific Corporation develops, manufactures, and markets medical devices used across a wide range of interventional specialties.
Last updated: 24/09/2026